Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (10)

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

    Leukemia, Vol. 35, Núm. 12, pp. 3542-3550

2019

  1. Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

    Cancer, Vol. 125, Núm. 13, pp. 2233-2241

2018

  1. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases

    Leukemia, Vol. 32, Núm. 11, pp. 2512-2518

  2. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

    Oncotarget, Vol. 9, Núm. 11, pp. 9714-9727

2017

  1. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

    Leukemia, Vol. 31, Núm. 2, pp. 318-324

  2. Current management of patients with chronic myelomonocytic leukemia

    Current Opinion in Oncology, Vol. 29, Núm. 1, pp. 79-87

  3. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies

    Cancer, Vol. 123, Núm. 24, pp. 4851-4859

  4. Preclinical activity of FF-10501-01, a novel inosine-5′-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia

    Leukemia Research, Vol. 59, pp. 85-92